Trans-Platinum Complexes with Diclofenac, Aspirin, and 2,6-Di-tert-Butylphenol Fragment: Synthesis and Biological Activity

T. A. Antonenko; Антоненко Т. А.; D. B. Shpakovskii; Шпаковский Д. Б.; Yu. A. Gracheva; Грачева Ю. А.; K. A. Lysenko; Лысенко К. А.; E. R. Milaeva; Милаева Е. Р.

doi:10.31857/S0132344X2360025X

Trans-Platinum Complexes with Diclofenac, Aspirin, and 2,6-Di-tert-Butylphenol Fragment: Synthesis and Biological Activity

Authors: Antonenko T.A.¹, Shpakovskii D.B.¹, Gracheva Y.A.¹, Lysenko K.A.¹, Milaeva E.R.¹
Affiliations:
1. Moscow State University, Moscow, Russia
Issue: Vol 49, No 10 (2023)
Pages: 624-631
Section: Articles
URL: https://cardiosomatics.ru/0132-344X/article/view/667473
DOI: https://doi.org/10.31857/S0132344X2360025X
EDN: https://elibrary.ru/NOTTIJ
ID: 667473

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

A series of σ-aryl platinum complexes with the sterically hindered phenol group of the general formula RPt[PPh3]2X (R = 3,5-di-tert-butyl-4-hydroxyphenyl; X = Cl (I), diclofenac (II), aspirin (III), and OOCR (IV)) is synthesized and characterized by 1H, 13C, and 31P NMR spectroscopy, IR spectroscopy, and elemental analysis. The molecular structure of compound I is determined by X-ray diffraction (XRD) (CIF file CCDC no. 2243100). The electron and hydrogen atom transfers are studied by spectrophotometry in the CUPRAC and DPPH tests. Complexes I, II, and IV are active reducing agents of Cu(II). The antioxidant activity is studied as the ability of the compounds to inhibit lipoxygenase (LOX-1B). Compound I is found to be an inhibitor of LOX-1B. The antiproliferative properties of the complexes are studied in vitro on the HCT-116, MCF-7, and A-549 cancer cells and WI-38 normal cells. The synthesized compounds have a lower antiproliferative activity than that of cisplatin.

Keywords

Pt(II) compounds, antioxidant activity, antiproliferative activity, aspirin, diclofenac

References

Guddneppanavar R., Saluta G., Kucera G.L., Bierbach U. // J. Med. Chem. 2014. V. 49. № 11. P. 3204.
Kelland L.R., Barnard F.G.C., Mellish K.J., Jones M. // Cancer Res. 1994. V. 8. P. 5618.
Cheng Q., Wang H., Min Y., Wang J. // R. Soc. Chem. 2014. V. 50. P. 7427.
Hager S., Ackermann C.J., Joerger M. et al. // Annals Oncology. 2016. V. 27. P. 975.
Intini F.P., Zajac J., Novohradsky V. et al. // Inorg. Chem. 2017. V. 56. № 3. P. 1483.
Ayoub S.S., Botting R.M., Joshi A.N. et al. // Mol. Cell. Biochem. 2009. V. 327. № 1–2. P. 101.
D’Autréaux B., Toleda M.B. // Nat. Rev. Mol. Cell Biol. 2007. V. 8. № 10. P. 813.
Sies H., Berndt C., Jones D.P. // Annu. Rev. Biochem. 2017. V. 86. P. 715.
Antonenko T.A., Shpakovsky D.B., Vorobyov M.A. et al. // Appl. Organomet. Chem. 2018. V. 32. Art. e4381.
Antonenko T.A., Gracheva Yu.A., Shpakovsky D.B. et al. // Int. J. Mol. Sci. 2023. V. 24. P. 2024.
Брауэр Г., Руководство по неорганическому синтезу. М.: Мир, 1986. Т. 5. С. 1814.
Милаев А.Г., Панов В.Б., Охлобыстин О.Ю. // Журн. общ. химии. 1981. Т. 51. № 12. С. 2715.
Malatesta L., Cariello C. // J. Chem. Soc. 1958. № 6. P. 2323.
Milaeva E.R., Rubezhov A.Z., Prokoph’ev A.I., Okhlobystin O.Yu. // J. Organomet. Chem. 1980. V. 188. № 3. P. C43.
Krause L., Herbst-Irmer R., Sheldrick G.M., Stalke D. // J. Appl. Crystallogr. 2015. V. 48. P. 3.
Sheldrick G.M. // Acta Crystallogr. A. 2015. V. 71. P. 3.
Sheldrick G.M. // Acta Crystallogr. C. 2015. V. 71. P. 3.
Apak R., Guglu K., Ozyurek M., Karademir S. // J. Agric. Food Chem. 2004. V. 52. P. 7970.
Brand-Williams W., Cuvelier M. E., Berset C. // Food Sci. Technol. 1995. V. 28. P. 25.
Ozturk I., Filimonova S., Hadjikakou S.K. // Inorg. Chem. 2010. № 7. P. 488.
Niks M., Otto M. // J. Immunol. Methods. 1990. V. 130. № 1. P. 149.
Ustafa M.O. // Agric. Food Chem. 2004. V. 52. P. 7970.